StockMacro
Company, fund or insider

Help

Menu

NextCure

$6.45 -8.1% in 6 monthsMarket cap $29.5M

NXTC on XNAS, Health Care, NextCure, Inc., job postings

Measures activity, not value. Not investment advice.

A delisting notice arrived as the company lost $41M on just $8.7M of cash, though insiders bought $140K.

  • GoodInstitutional holders rose to 33 from 30, up 10%

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Industry
Pharmaceutical preparations (Health Care)
Employees
40
Website
nextcure.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 22 Jan 2027 (an estimate: a year ago it reported on 23 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $6.8M.
Quarter to 31 Dec 2021: revenue –, net income -$16.9MQuarter to 31 Mar 2022: revenue –, net income -$20.6MQuarter to 30 Jun 2022: revenue –, net income -$17.9MQuarter to 30 Sep 2022: revenue –, net income -$18.9MQuarter to 31 Dec 2022: revenue –, net income -$17.3MQuarter to 31 Mar 2023: revenue –, net income -$16.1MQuarter to 30 Jun 2023: revenue –, net income -$17.9MQuarter to 30 Sep 2023: revenue –, net income -$14.3MQuarter to 31 Dec 2023: revenue –, net income -$14.5MQuarter to 31 Mar 2024: revenue –, net income -$17.1MQuarter to 30 Jun 2024: revenue –, net income -$15.4MQuarter to 30 Sep 2024: revenue –, net income -$11.5MQuarter to 31 Dec 2024: revenue –, net income -$11.6MQuarter to 31 Mar 2025: revenue –, net income -$11.0MQuarter to 30 Jun 2025: revenue –, net income -$26.8MQuarter to 30 Sep 2025: revenue –, net income -$8.6MQuarter to 31 Dec 2025: revenue –, net income -$9.4MQuarter to 31 Mar 2026: revenue –, net income -$9.8MQuarter to 30 Jun 2026: revenue –, net income -$14.9MQuarter to 30 Sep 2026: revenue –, net income -$6.8M
31 Dec 2021RevenueNet incomeNet losstallest bar $26.8M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$6.8M
30 Jun 2026–-$14.9M
31 Mar 2026–-$9.8M
31 Dec 2025–-$9.4M
30 Sep 2025–-$8.6M
30 Jun 2025–-$26.8M
31 Mar 2025–-$11.0M
31 Dec 2024–-$11.6M
30 Sep 2024–-$11.5M
30 Jun 2024–-$15.4M
31 Mar 2024–-$17.1M
31 Dec 2023–-$14.5M
30 Sep 2023–-$14.3M
30 Jun 2023–-$17.9M
31 Mar 2023–-$16.1M
31 Dec 2022–-$17.3M
30 Sep 2022–-$18.9M
30 Jun 2022–-$17.9M
31 Mar 2022–-$20.6M
31 Dec 2021–-$16.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$41.0M -$58.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$6.40 -$19.62
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -281% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $8.7M $29.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.20
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.4 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
NextCureNXTC (this company) $29.5Mloss–––
Serina TherapeuticsSER $29.8Mloss–––
NanoViricidesNNVC $29.1Mloss–––
Rein TherapeuticsRNTX $29.1Mloss–––
AYTU BioPharmaAYTU $28.9Mloss0.49-8.1%-34.3%
ProMIS NeurosciencesPMN $28.4Mloss–––

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$140K

bought $140K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+10%

33 13F filers vs 30

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

67%

3.1M shares held by 13F filers (30 Sep 2026) of 4.6M outstanding (9 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.0%

184K shares sold short (30 Oct 2026) of 4.6M outstanding (9 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.0

184K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-17%

221K shares sold short in the report before, 184K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

12%

12% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

20

20 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

20 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $6.45 on 20 Nov 2026, -30% over 12 months (12-month range $1.60 to $14.27)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $1.7M in the last 12 months (the 12 months before: $0).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.
Capital spending per quarter. Capital spending $170K in the latest quarter, -39% on a year earlier.
Institutional holders (13F filers). 33 13F filers reported holding it in the latest 13F quarter, +94% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
20 Nov 20268-K and other filingsReceived Nasdaq notice: stockholders' equity of $5.5M below $10.0M minimum; plan due Jan 4, 2027, or Avere merger expected mid-December 2026
30 Oct 20268-K and other filingsDirector or officer change
30 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Jul 20268-K and other filingsRestructuring costs announced
14 Jul 20268-K and other filingsDirector or officer change
25 Jun 20268-K and other filingsDirector or officer change
25 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Dec 20258-K and other filingsPrivate placement of securities (Form D)
25 Aug 20258-K and other filingsDirector or officer change
25 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Feb 20258-K and other filingsDelisting notice or listing transfer
18 Jun 20248-K and other filingsDirector or officer change
18 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Apr 2024Sharp changeShort interest spike: short interest spike, 994K vs usual 215K (2024-03-28); 3.1x the same period a year earlier
2 Apr 2024Sharp changeShort interest spike: short interest spike, 840K vs usual 215K (2024-03-15); 2.5x the same period a year earlier
19 Jul 20238-K and other filingsDirector or officer change
19 Jul 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Jul 2026: $88K published
Month from 1 Aug 2026: $1.4M published
Month from 1 Oct 2026: $54K published
Month from 1 Nov 2026: $87K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2022: 2 published
Capital spending per quarter
Quarter ended 31 Dec 2021: $825K, -16% on a year earlier; public on 4 Mar 2022
Quarter ended 31 Mar 2022: $305K, -60% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $414K, +94% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $532K, -4.3% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $865K, +4.8% on a year earlier; public on 3 Mar 2023
Quarter ended 31 Mar 2023: $248K, -19% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $280K, -32% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $279K, -48% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Mar 2024: $37K, -85% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $301K, +7.5% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $170K, -39% on a year earlier; public on 8 Nov 2024
Institutional holders (13F filers)
31 Dec 2021 report: 66; public on 14 Feb 2022
31 Mar 2022 report: 54; public on 16 May 2022
30 Jun 2022 report: 48; public on 15 Aug 2022
30 Sep 2022 report: 46; public on 14 Nov 2022
31 Dec 2022 report: 41; public on 14 Feb 2023
31 Mar 2023 report: 42; public on 15 May 2023
30 Jun 2023 report: 42; public on 14 Aug 2023
30 Sep 2023 report: 40; public on 14 Nov 2023
31 Dec 2023 report: 41; public on 14 Feb 2024
31 Mar 2024 report: 47; public on 15 May 2024
30 Jun 2024 report: 48; public on 14 Aug 2024
30 Sep 2024 report: 43; public on 14 Nov 2024
31 Dec 2024 report: 46; public on 14 Feb 2025
31 Mar 2025 report: 37; public on 15 May 2025
30 Jun 2025 report: 30; public on 14 Aug 2025
30 Sep 2025 report: 17; public on 14 Nov 2025
31 Dec 2025 report: 23; public on 17 Feb 2026
31 Mar 2026 report: 26; public on 15 May 2026
30 Jun 2026 report: 30; public on 14 Aug 2026
30 Sep 2026 report: 33; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F funds opening a position at 10 (30 Sep 2026), 2.5× its normal reading; higher than 67% of its own history.
  • Insider net buying (open market): Insiders bought a net $1.7M in the last 12 months (the 12 months before: $0).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months.
  • Capital spending per quarter: Capital spending $170K in the latest quarter, -39% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 13 insider trades

Last 90 days: no sales; 3 purchases, $140K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Nov 2026ADAR1 Capital Management, LLC and 1 other10% ownerBuy12,333$5.10$63KForm 4
9 Nov 2026ADAR1 Capital Management, LLC and 1 other10% ownerBuy4,686$5.10$24KForm 4
27 Oct 2026ADAR1 Capital Management, LLC and 1 other10% ownerBuy10,851$4.95$54KForm 4
12 Aug 2026Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. and 5 othersFormer 10% OwnerSell30,000$6.16$185KForm 4
3 Aug 2026ADAR1 Capital Management, LLC and 1 other10% ownerBuy329,153$4.93$1.6MForm 4
29 Jul 2026ADAR1 Capital Management, LLC and 1 other10% ownerBuy17,608$4.98$88KForm 4
19 Nov 2019Sofinnova Venture Partners IX, L.P. and 4 others10% ownerBuy150,000$36.75$5.5MForm 4
15 May 2019Sofinnova Management IX, L.L.C. and 4 others10% ownerBuy400,000$15.00$6.0MForm 4

33 institutions reported shares at the end of Q3 2026, 67% of the shares outstanding; 10 opened a position, 7 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
ADAR1 Capital Management, LLC722K15.8%$3.6MNew+722K
Adage Capital Partners GP, L.L.C.377K8.24%$1.9M+100K+36%
Affinity Asset Advisors, LLC292K6.38%$1.5M+250K+596%
Blackstone Inc.224K4.89%$1.1M
Sofinnova Investments, Inc.223K4.86%$1.1MNo change
Eversept Partners, LP185K4.05%$929KNew+185K
Vanguard Capital Management LLC157K3.43%$786KNo change
Citadel Advisors LLC111K2.42%$554KNew+111K
Verition Fund Management LLC93K2.03%$466KNew+93K
Soleus Capital Management, L.P.90K1.97%$451KNew+90K

Company events

All 32 company events

In 12 months: 3 director or officer changes, 2 major agreements, 1 private placement, 1 restructuring. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Nov 2026Received Nasdaq notice: stockholders' equity of $5,503,000 below $10.0M minimum; plan due Jan 4, 2027, or Avere merger expected mid-December 20268-K
30 Oct 2026Director or officer change8-K
3 Sep 2026Signed a major agreement8-K
14 Jul 2026Director or officer change; Signed a major agreement; Restructuring costs announcedSame filing: change of control8-K
25 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
9 Dec 2025Private placement of securities (Form D)$21.5M sold of $21.5M offeredD
17 Nov 2025Signed a major agreementSame filing: sold shares privately8-K
25 Aug 2025Director or officer change8-K

The 5 newest of 64 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 20 Nov 2026Filings record

    Received Nasdaq notice: stockholders' equity of $5.5M below $10.0M minimum; plan due Jan 4, 2027, or Avere merger expected mid-December 2026

  2. 13 Nov 2026Insiders record

    ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 12,333 shares of NXTC ($62,897)

  3. 9 Nov 2026Insiders record

    ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 4,686 shares of NXTC ($23,899)

  4. 30 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 30 Oct 2026Filings record

    Director or officer change

  6. 27 Oct 2026Insiders record

    ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 10,851 shares of NXTC ($53,691)

  7. 4 Aug 2026Insiders record

    ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 329,153 shares of NXTC ($1.6M) (dated 3 Aug 2026)

  8. 30 Jul 2026Insiders record

    ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 17,608 shares of NXTC ($87,720) (dated 29 Jul 2026)

  9. 14 Jul 2026Filings record

    Director or officer change

  10. 14 Jul 2026Filings record

    Restructuring costs announced

  11. 25 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 25 Jun 2026Filings record

    Director or officer change

  13. 10 Dec 2025Filings record

    Private placement of securities (Form D) (dated 9 Dec 2025)

  14. 25 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 25 Aug 2025Filings record

    Director or officer change

  16. 3 Feb 2025Filings record

    Delisting notice or listing transfer

  17. 18 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 18 Jun 2024Filings record

    Director or officer change

  19. 10 Apr 2024Short interest and volume change

    had 994K shares sold short in the 28 Mar 2024 report, 3.1× the same report last year.

    Same report last year: 318K; its normal report is 215K.

    See the evidence
    This period
    994K (the 28 Mar 2024 report)
    Normal report (median of 24 earlier)
    215K
    Typical spread (median absolute deviation)
    20K
    How far from its usual level
    +15.6
    Same report last year
    318K
    History used
    1,779 days
    2023-03-31: 318K2023-04-14: 269K2023-04-28: 258K2023-05-15: 269K2023-05-31: 236K2023-06-15: 252K2023-06-30: 270K2023-07-14: 222K2023-07-31: 214K2023-08-15: 210K2023-08-31: 211K2023-09-15: 206K2023-09-29: 230K2023-10-13: 200K2023-10-31: 197K2023-11-15: 197K2023-11-30: 196K2023-12-15: 230K2023-12-29: 216K2024-01-12: 123K2024-01-31: 109K2024-02-15: 118K2024-02-29: 123K2024-03-15: 840K2024-03-28: 994K
    the 28 Mar 2024 report24 earlier reportsnormal: 215K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 27 Mar 2024Short interest and volume change

    had 840K shares sold short in the 15 Mar 2024 report, 2.5× the same report last year.

    Same report last year: 330K; its normal report is 215K.

    See the evidence
    This period
    840K (the 15 Mar 2024 report)
    Normal report (median of 24 earlier)
    215K
    Typical spread (median absolute deviation)
    20K
    How far from its usual level
    +12.5
    Same report last year
    330K
    History used
    1,766 days
    2023-03-15: 330K2023-03-31: 318K2023-04-14: 269K2023-04-28: 258K2023-05-15: 269K2023-05-31: 236K2023-06-15: 252K2023-06-30: 270K2023-07-14: 222K2023-07-31: 214K2023-08-15: 210K2023-08-31: 211K2023-09-15: 206K2023-09-29: 230K2023-10-13: 200K2023-10-31: 197K2023-11-15: 197K2023-11-30: 196K2023-12-15: 230K2023-12-29: 216K2024-01-12: 123K2024-01-31: 109K2024-02-15: 118K2024-02-29: 123K2024-03-15: 840K
    the 15 Mar 2024 report24 earlier reportsnormal: 215K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 19 Jul 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 19 Jul 2023Filings record

    Director or officer change

  23. 4 Oct 2021Filings record

    Director or officer change

  24. 24 Sep 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  25. 24 Sep 2021Filings record

    Director or officer change

  26. 24 Feb 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 24 Feb 2021Filings record

    Director or officer change

  28. 14 Sep 2020Filings record

    Director or officer change

  29. 31 Jul 2020Filings record

    Director or officer change

  30. 17 Jul 2020Filings record

    Director or officer change

  31. 13 Jul 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 13 Jul 2020Filings record

    Director or officer change

  33. 30 Mar 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 30 Mar 2020Filings record

    Director or officer change

  35. 13 Jan 2020Filings record

    A major agreement ended

  36. 20 Nov 2019Insiders record

    Sofinnova Venture Partners IX, L.P. (ten percent owner) and 4 other(s) bought 150,000 shares of NXTC ($5.5M) (dated 19 Nov 2019)

  37. 14 Nov 2019Filings record

    Registered new securities for sale (S-1)

  38. 12 Nov 2019Filings record

    Registered new securities for sale (S-1)

  39. 2 Oct 2019Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 2 Oct 2019Filings record

    Director or officer change

Showing the newest 40 of 53 entries; narrow the window or the kind of data to see older ones.

Not listed: 73 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001661059
Ticker
NXTC
Domain
nextcure.com
Employer name
NEXTCURE, INC. (1 unverified)
Hq location
MD|BALTIMORE|21209 (1 unverified)
Name
NextCure, Inc.
  • DOL H-1B labor condition applications and PERM certifications10 data points2 Mar 2020 to 22 Aug 2022
  • SEC Form 13F institutional holdings270 data points30 Jun 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)100 records11 Jan 2016 to 20 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)470 data points31 Dec 2017 to 9 Nov 2026
  • SEC Form 4 insider transactions13 records, 36 data points13 May 2019 to 13 Nov 2026
  • FINRA short interest (twice monthly)536 data points15 May 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3792 data points9 May 2019 to 20 Nov 2026